Clinical Trial Update: GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating induction therapy with gemcitabine plus cisplatin in combination with nimotuzumab and sintilimab for locally advanced nasopharyngeal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Nimotuzumab (nimotuzumab)
• Sintilimab (sintilimab)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Locally Advanced Nasopharyngeal Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING